Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Oct 1, 2026 (in 31 days)
Similar opportunities open now
- Metastasis Research Network (U54 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 25 daysUp to $1.3M
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 71 daysUp to $150K
- NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Mar 2029
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 71 daysUp to $300K
- GREGoRi Technology Integration Center (U01, Clinical Trials Optional)Same funderOpenNational Institutes of HealthCloses in 60 daysUp to $2.3M
Classification and identifiers
- Solicitation number
- RFA-CA-27-005
- Assistance listing (CFDA)
- 93.394
Amount
Amount not published by the funder
Who can apply
Private colleges and universities and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations…
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: ...